Form 4: MYGN Executive's Tax Withholding on RSU Vesting

Myriad Genetics EVP Margaret Ancona reported the withholding of 958 shares of common stock to cover tax obligations related to vested restricted stock units.

Summary

• Margaret Ancona, EVP, Strategy & Transformation at Myriad Genetics Inc. (MYGN), reported a transaction involving company common stock.
• The transaction, dated September 21, 2025, involved the disposition of 958 shares.
• These shares were withheld by the company to satisfy tax withholding obligations in connection with the vesting of restricted stock units (RSUs) granted to Ms. Ancona.
• The value of the shares withheld for tax purposes was $7.77 per share.
• Following this transaction, Ms. Ancona beneficially owns 127,726 shares of Myriad Genetics common stock directly.
• The number of shares withheld was determined based on the closing price of Myriad common stock on September 19, 2025.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary tax withholding event related to executive compensation, which is neutral in terms of company performance or outlook.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This transaction is a routine event in executive compensation, where shares from vested restricted stock units are withheld by the company to cover the executive's tax liabilities. It is a common practice across publicly traded companies and does not typically reflect a discretionary sale by the executive.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary transaction related to executive compensation and does not signal a change in management's outlook or company fundamentals.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary tax withholding event for an executive's vested restricted stock units, executed under a 10b5-1 plan. It provides no new information regarding the company's financial performance, strategic direction, or operational outlook that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, as the filing does not present a catalyst for either buying or selling the stock.

Keywords

MYRIAD GENETICS, MYGN, Form 4, Insider Transaction, Executive Compensation, RSU Vesting, Tax Withholding, Rule 10b5-1